Entrada Therapeutics (TRDA) Shares Outstanding (2020 - 2026)

Entrada Therapeutics has reported Shares Outstanding for 7 years, with the latest figure at $38.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 2.31% year-over-year to $38.8 million; the trailing twelve-month figure through Mar 2026 stood at $38.8 million (up 2.31% YoY), and the FY2025 full-year result was $38.3 million, up 1.89% from the prior year.
• Shares Outstanding for Q1 2026 stood at $38.8 million, up from $38.3 million in the prior quarter.
• The five-year high for Shares Outstanding was $38.8 million in Q1 2026, with the low at $31.3 million in Q1 2022.
• Average Shares Outstanding over 5 years is $35.0 million, with a median of $33.6 million recorded in 2024.
• Peak annual rise in Shares Outstanding reached 2358.97% in 2022, while the deepest fall reached 0.55% in 2022.
• Tracing TRDA's Shares Outstanding over 5 years: stood at $31.4 million in 2022, then climbed by 6.51% to $33.4 million in 2023, then advanced by 12.37% to $37.6 million in 2024, then grew by 1.89% to $38.3 million in 2025, then increased by 1.4% to $38.8 million in 2026.
• The last three Shares Outstanding figures came in at $38.8 million (Q1 2026), $38.3 million (Q4 2025), and $38.2 million (Q3 2025), per Business Quant data.

Peer Comparison